Peptide library / Digestive & weight / Cagrilintide
Cagrilintide
An investigational long-acting amylin analog from Novo Nordisk, tested alone and combined with semaglutide.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Weight loss in obesity, alone or with semaglutideLarge trials
- Blood sugar control in type 2 diabetesLarge trials
How it is thought to work
Amylin is a hormone released with insulin that promotes fullness. Cagrilintide mimics it with a longer half-life, and acts through a different pathway than GLP-1.
What the evidence shows
In the REDEFINE 1 trial, the combination with semaglutide produced average weight loss above 20 percent at 68 weeks, while cagrilintide alone produced about 12 percent. The combination is being filed with regulators.
Safety and unknowns
Nausea and vomiting were the most common effects and were mostly mild to moderate. Long-term data are limited.
Regulatory status
Not approved as a standalone product at the time of writing. Regulatory status changes quickly, so check the FDA database.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Dulaglutide
FDA-approvedA once-weekly GLP-1 receptor agonist used in type 2 diabetes with proven heart benefit.
Ecnoglutide
In clinical trialsAn investigational weekly GLP-1 receptor agonist developed in China by Sciwind Biosciences.
BPC-157
Wellness and performanceA 15 amino acid gut-protein fragment studied almost entirely in animals, with growing interest in compounding.
General information, not medical advice. Do not buy or inject unregulated peptides.